The results showed that AS-IV improved the symptoms of HFpEF mice mainly in improving myocardial hypertrophy, pulmonary congestion, reducing SBP, DBP and ANP, NT-proBNP, and obesity and dyslipidemia. Here, NPPB is linked to obesity disorder.